the council of ministers resolution no. 265 dated 30th shawwal 1422 h provided for the transformation of king faisal specialist hospital & research center to a "public institution". The resolution provided grounds for the incorporation of a limited liability company affiliated to king faisal specialist hospital & research center in partnership with the private sector. According to clause (3), para (b), article (6) of the corporate bylaws, the stipulated resources of the institution consist of the following: (b) "income earned by the company from the activities that fall within its specialization"; and (e) "any other additional resources as decided by the board of directors". In line with these provisions, a board of directors' decision was issued under # 40/m/1427/7 dated 01/05/1427 h (corresponding to 28/05/2006 g) endorsing the incorporation of the arabian diagnostics company limited in partnership with prince sultan bin abdul aziz charitable foundation with a 5% share of the company's equity. The name of the company was subsequently amended to "saudi diagnostics company limited". The company's prospective expansion of its core business, and so as to enable it to partner with the private sector institutions, it was converted on 21/04/1434 h, corresponding to 03/03/2013 g, from a limited liability company to a holding company, and its name was changed to "saudi diagnostics holding company".
Since its inception in 2007 g, the saudi diagnostics holding co. Envisioned itself as leader of the diagnostics industry not only in the kingdom, but in the entire mena region. Towards this end the company is sparing no effort in tuning up its services to a world-class standard. Leaning on the established heritage of its owners, i.E. King faisal specialist hospital & research center and prince sultan bin abdul aziz al saud charity foundation, it is well positioned, god willing, to achieve all its aspirations and goals.
1. Provision of molecular diagnostic service to the health sector institutions and research centers in the kingdom of saudi arabia to the highest world-class standards in line with similar service levels in the developed countries.
2. Acting as a prime driving force for encouraging and motivating the establishment of new specialized biotechnology entities and sectors in the kingdom of saudi arabia.
3. Fostering innovation and development projects by doctors and researchers and elevating the level of citizens and community awareness of human pathogenic genomic diseases through genetic factors' diagnostic surveys and determining the relevant therapeutic and preventative ways to manage or avoid them.